NCT05588388 - Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 28, 2026

Study Completion Date

December 28, 2027

Conditions

Extensive-stage Small-cell Lung CancerLiver Metastases

Interventions

DRUG

Bevacizumab

Addition of Bevacizumab to current standard of care treatment (atezolizumab, carboplatin and etoposide) followed by maintenance Bevacizumab plus Atezolizumab for patients with ES-SCLC with LM

Trial Locations (3)

48105

RECRUITING

V.A. Ann Arbor Healthcare System, Ann Arbor

48109

RECRUITING

University of Michigan, Ann Arbor

90048

RECRUITING

Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles